Guardant Health (NASDAQ: GH) reported Q2 EPS of ($0.44), $0.28 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $232.1 million versus the consensus estimate of $211.27 million.

GUIDANCE:

Guardant Health sees FY2025 revenue of $915-925 million, versus the consensus of $885.1 million.

Within this revenue range:

Oncology revenue is now expected to grow approximately 20% year over year in 2025, compared to prior guidance of approximately 18% growth. Oncology volume is now expected to accelerate to greater than 27% growth in 2025 compared to 20% growth in 2024.
Screening revenue is now expected to be in the range of $55 to $60 million, driven by Shield volume of 68,000 to 73,000 tests. This compares to the prior range of $40 to $45 million and 52,000 to 58,000 tests.
Biopharma & Data revenue growth is now expected to be in the mid-teens range, compared to prior expectations of low double-digits.

For earnings history and earnings-related data on Guardant Health (GH) click here.